A leukemia drug know as Nilotinib that is already on the market might also be able to treat the hallmark signs of Parkinson’s disease. This break through study represents the first time a therapy appears to reverse cognitive and motor decline in patients with Parkinson’s disease, according to the researchers.

Specifically, this trial builds on animal studies conducted by Georgetown University assistant professor of neurology Dr. Charbel Moussa. The most dramatic changes in the first phase of the trail consisted of investigators observing that one individual confined to a wheelchair was able to walk again and three others who could not talk were able to hold conversations after taking Nilotinib for six months.

Learn more at Forbes